1. A composition with prolonged release of an amino-C alkyl nitrate and pharmaceutically acceptable salts thereof, wherein the release occurs within 4-24 chasov.2. Sustained release formulation of claim. 1, in which the amino-S-S-alkyl nitrate is selected from 4-aminobutilnitrata, 3-aminopropilnitrata, 2-amino-1-and 2-metiletilnitrata aminoetilnitrata.3. Sustained release formulation of claim. 1, in which the amino-S-S-alkyl nitrate is 2-aminoetilnitrat.4. Sustained release formulation of claim. 3, wherein the pharmaceutically acceptable salt of 2-aminoetilnitrata represents tozilat.5. The sustained release composition according to any one of claims. 1-4, further comprising another pharmaceutically active compound in combination with a fixed dozoy.6. Sustained release formulation of claim. 5, wherein said other pharmaceutically active compound is selected from the group of angiotensin receptor blockers, inhibitors of angiotensin enzyme renin antagonists, beta-blockers, calcium channel blockers, endothelin antagonists, statins, biguanides, glitazones, sulfonylureas, antagonists sodium-dependent glucose transporter (SGLT2), inhibitors of dipeptidyl peptidase-4 (DPP-4), antithrombotic agents, antiplatelet agents, anticoagulants, antiangi cial drugs, vasodilators and aldosterona.7 antagonists. Sustained release formulation of claim. 5, wherein said other pharmaceutically active compound is selected from valsartan, azilsartana, mazisentana, cilostazol, pioglitazone, sitagliptin and linagliptina.8. composition1. Композиция с пролонгированным высвобождением амино-С2-С6-алкил нитрата и его фармацевтически приемлемых солей, где высвобождение происходит в течение 4-24 часов.2. Композиция с пролонгированным высвобождением по п. 1, в которой амино-С2-С6-алкилнитрат выбран из 4-аминобутилнитрата, 3-аминопропилнитрата, 2-амино-1-метилэтилнитрата и 2-аминоэтилнитрата.3. Композиция с пролонгированным высвобождением по п. 1, в которой амино-С2-С6-алкилнитрат представляет собой 2-ами
